Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

VaxDesign, is a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures, and markets in vitro models of the human immune system. Its Modular IMmune In vitro Construct (MIMIC®) technology melds immunology with engineering to find elegant solutions to complex biological problems. The MIMIC® system was initially developed for the Rapid Vaccine Assessment Program of the U.S. Defense Advanced Research Projects Agency (DARPA) and has since been funded by several other U.S. federal agencies, such as the Defense Threat Reduction Agency, Biomedical Advanced Research and Development Authority, Army Chemical Biological Medical Systems (CBMS), and National Institute of Standards and Technology (NIST).

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

MatTek Corp., a subsidiary of BICO Group AB, is a company headquartered in Ashland, MA. The firm produces normal non-transformed, human cell-derived and three-dimensional organotypic in vitro tissue models. It was founded in 1985 by Robert E. Cohen. Alex Armento has been the CEO since 2018. On March 22, 2021 BICO Group AB acquired MatTek Corp. for $71.96 million.\nThe company says this about itself: MatTek was founded in 1985 and began producing human tissue models as reliable replacements for animal testing. MatTek’s skin, ocular, oral, respiratory, and intestinal tissue models are used to assess safety and efficacy throughout the pharmaceutical, cosmetics, personal care, and household product industries. These advanced tissue models empower companies to achieve their goals of non-animal testing while lowering testing costs and providing human-relevant results. The company has expanded its offerings to include cultureware, primary human cells and media, 3Diy kits, and testing services in support of its mission to advance innovative in vitro science through the production of synergistic life science products and services.

MEDRAD develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer Medical Care.

J-TEC is a bio-venture enterprise founded on the premise that J-TEC will "develop a basic tissue regeneration medical treatment based on the science of tissue engineering, which will bring a qualitative change in medical treatment practices, and thus develop into a business that will transform 21st century medical treatment itself". The business groups being developed by J-TEC include its "Regenerative Medicine Business", with the main objective of developing, manufacturing and selling tissue-engineered medical products and related products, and as such, is subject to the Pharmaceutical Affairs Law* and a second business group called the "R&D Support Business", which is not subject to this law. *The Pharmaceutical Affairs Law states that “the objective of this law is to regulate matters necessary for securing the quality, efficacy and safety of pharmaceuticals, quasi-drugs, cosmetics and medical devices, while taking necessary steps to promote research and development of pharmaceuticals and medical devices in high necessity, and thereby improve public health and hygiene.” (Article 1 of the Pharmaceutical Affairs Law)

The Korea Astronomy and Space Science Institute (KASI) is the national research institute in astronomy and space science of South Korea funded by the South Korean Government. Its headquarters are located in Daejeon, in the Daedeok Science Town. Research at KASI covers main areas of modern astronomy, including Optical Astronomy, Radio Astronomy, Space Science, and Theoretical Astronomy.

Tissuemed LTD is a UK-based medical technology company that develops tissue-based therapeutic devices like the first tissue heart valve to gain regulatory approval in Europe. The company also specializes in bioadhesives, adhesive films to prevent air, blood and fluid leaks encountered in surgery. The company has a reputation for innovation dating back over twenty years. Following divestiture of the heart valve business in 1999, Tissuemed focused its considerable scientific expertise on the development of surgical sealants. Five years of research and development yielded the TissuePatch™ product family, which is now at the core of the company’s activities. These unique surgical films have been designed specifically to help surgeons to effectively seal tissues against leakage air, blood and other fluids, including Cerebrospinal Fluid (CSF).

Menicon creates contact lenses. In response to consumer demand, they increase the range of products and services available. Animal ophthalmic care uses the same technology that was developed for contact lenses for people. They aid in the growth of veterinary ophthalmology in cooperation with veterinarians. Use the technology that has been developed for the creation of care and contact lenses in the environmental business sector.

Reliance Life Sciences is a diverse and integrated biotechnology initiative of the Reliance Group of companies. The Reliance Group is India’s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group’s activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom. The Group’s flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company. Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics.

The French Institut de radioprotection et de sûreté nucléaire (IRSN) ("Radioprotection and Nuclear Safety Institute") located in Fontenay-aux-Roses is a public official establishment with an industrial and commercial aspect (EPIC) created by the AFSSE Act (Agence française de sécurité sanitaire de l'environnement et du travail (fr) - French Agency of Sanitary Environmental Security) and by February 22, 2002 decreed n°2002-254. The IRSN is placed under the conjoint authority of the Defence minister, the Environmental minister, the Industry minister and the Health and Research minister.

Part of Cornhill Corp. LLP, Picker International, Inc. is an American company that manufactures heating equipment.

Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.

Eben Bayer and Gavin McIntyre are fascinated by mushrooms growing on wood chips and observing how the fungal mycelium strongly bonds the wood chips together. This inspired them to think of new ways of using mycelium as a resin. In a class at Rensselaer called Inventor's Studio, they applied this new process for binding together insulating particles, creating Greensulate. Rather than just decreasing the environmental impact of conventional polystyrene foams, this invention creates a whole new paradigm where composite materials are literally grown, harnessing the incredible efficiency of nature. Shortly after founding the company, they won small grants from the American Society of Mechanical Engineers (ASME) and the National Collegiate Inventors and Innovators Alliance (NCIIA). This funding was used to create initial samples of the material. This proof of concept enabled the company to win bigger grants from the New York State Energy Research and Development Authority (NYSERDA) and the Environmental Protection Agency (EPA) to further develop the products. Since then, Ecovative has won many more awards and grants that have enabled the company to continue to grow and accelerate the production of these revolutionary eco-friendly materials. At Ecovative, they are passionate about sustainability. That is why they are working with nature to replace unsustainable plastics and foams with natural composites. Using innovative new materials and radical new technologies, their products perform at least as well as current state-of-the-art synthetics, but at a lower cost to both you and the environment.